Home > Insider Trading > Filing (0001209191-13-053649)

Filing Details

Accession Number:: 0001209191-13-053649
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2013-11-21 20:02:30
Reporting Period:: 2013-11-19

Filing Date:: 2013-11-21
Accepted Time:: 2013-11-21 20:02:30
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1347178	Vanda Pharmaceuticals Inc.	VNDA	Pharmaceutical Preparations (2834)	030491827

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1532513	Robert Repella	2200 Pennsylvania Avenue Suite 300E Washington DC 20037	Svp & Chief Commercial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2013-11-19	2,885	$12.07	21,490	No	4	S	Direct
Common Stock	Acquisiton	2013-11-20	40,515	$5.90	62,005	No	4	M	Direct
Common Stock	Disposition	2013-11-20	40,515	$11.89	21,490	No	4	S	Direct
Common Stock	Acquisiton	2013-11-21	23,040	$5.90	44,530	No	4	M	Direct
Common Stock	Acquisiton	2013-11-21	34,570	$3.12	79,100	No	4	M	Direct
Common Stock	Disposition	2013-11-21	64,100	$12.12	15,000	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2013-11-20	40,515	$0.00	40,515	$5.90
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2013-11-21	23,040	$0.00	23,040	$5.90
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2013-11-21	34,570	$0.00	34,570	$3.12

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
189,485	2021-10-24	No	4	M	Direct
166,445	2021-10-24	No	4	M	Direct
21,680	2022-12-06	No	4	M	Direct

Footnotes

Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of certain Restricted Stock Units.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.03 to $12.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2), (3) and (4) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.80 to $12.115, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.80 to $12.46, inclusive.
The option becomes exercisable with respect to 25% of the shares after 12 months of continuous service with the Issuer, with the balance becoming exercisable in equal monthly installments over the next 36 months of continuous service thereafter.
50% of the shares subject to this option shall vest in 48 equal monthly installments beginning January 7, 2013 (the "Initial Vesting Date"), provided Reporting Person remains continuously employed by the Issuer through the Initial Vesting Date. 50% of the shares subject to this option shall vest upon acceptance by the U.S. Food and Drug Administration of the Issuer's New Drug Application Filing for tasimelteon for the treatment of Non-24-Hour Disorder (the "Vesting Event"), provided Reporting Person remains continuously employed by the Issuer through the Vesting Event.